Related Experiment Video
Updated: Jun 4, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Determinants of interferon β efficacy in patients with multiple sclerosis
Joep Killestein1, Chris H Polman
1Department of Neurology (MS Center Amsterdam), VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. j.killestein@vumc.nl
Nature Reviews. Neurology
|March 3, 2011
Summary
Predicting multiple sclerosis (MS) treatment response is crucial. Early identification of non-responders to interferon beta (IFN-β) using MRI lesions and neutralizing antibodies allows for timely treatment adjustments.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacogenomics
Background:
- Multiple sclerosis (MS) patients often show disease activity despite treatment.
- Interferon beta (IFN-β) is effective, but individual patient response factors are unclear.
- Identifying predictors of IFN-β efficacy is vital for personalized MS management.
Purpose of the Study:
- To review current research on predicting response to interferon beta (IFN-β) in multiple sclerosis (MS).
- To offer a practical framework for integrating clinical, biological, and MRI data for therapeutic management.
- To guide early treatment adjustments for non-responding MS patients.
Main Methods:
- Review of existing studies on interferon beta (IFN-β) efficacy and response markers in multiple sclerosis (MS).
- Analysis of clinical data, biological markers (e.g., neutralizing antibodies), and MRI measures of disease activity.
- Synthesis of evidence to identify predictive factors for IFN-β treatment outcomes.
Main Results:
- Development of new MRI lesions within 6-24 months post-IFN-β initiation predicts poor response.
- Persistently high titers of neutralizing antibodies against IFN-β diminish therapeutic effects.
- Few reliable biomarkers have emerged, highlighting the need for integrated assessment.
Conclusions:
- Integrating clinical data, MRI findings, and antibody levels can improve prediction of IFN-β response in MS.
- Early identification of non-responders facilitates timely switching to alternative therapies.
- Personalized therapeutic strategies are essential for optimizing MS management.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...